ANI Pharmaceuticals (ANIP) Financials

ANI Pharmaceuticals logo
$69.99 -0.90 (-1.27%)
Closing price 04:00 PM Eastern
Extended Trading
$70.04 +0.05 (+0.07%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for ANI Pharmaceuticals

Annual Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
15 3.93 -1.08 15 6.09 -23 -43 -50 17 -20 77
Consolidated Net Income / (Loss)
15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Net Income / (Loss) Continuing Operations
15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Total Pre-Tax Income
22 8.68 16 20 3.16 -26 -56 -63 20 -22 96
Total Operating Income
33 20 28 35 16 -16 -40 -35 47 0.58 111
Total Gross Profit
64 80 98 129 143 121 116 178 305 364 542
Total Revenue
76 129 177 202 207 208 216 316 487 614 883
Operating Revenue
76 129 177 202 207 208 216 316 487 614 883
Total Cost of Revenue
13 49 79 73 63 87 101 139 182 250 341
Operating Cost of Revenue
13 49 79 73 63 87 101 139 182 250 341
Total Operating Expenses
31 60 69 93 127 137 155 213 258 364 431
Selling, General & Admin Expense
21 28 32 44 56 65 84 124 162 250 318
Research & Development Expense
2.87 2.91 9.07 15 20 16 11 22 34 45 52
Depreciation Expense
6.90 22 28 34 45 45 47 57 60 68 91
Impairment Charge
0.00 6.69 0.90 0.00 0.08 0.45 2.37 - 0.00 7.60 0.77
Restructuring Charge
- - - - - 0.00 0.00 5.68 1.13 0.00 0.00
Other Special Charges / (Income)
- - - - 0.00 0.00 9.25 3.76 1.43 -5.97 -31
Total Other Income / (Expense), net
-11 -11 -12 -15 -13 -9.95 -16 -27 -27 -23 -15
Interest Expense
- - - - - - - 0.00 0.00 7.47 0.00
Interest & Investment Income
-11 -11 -12 -15 -13 -9.45 -12 -28 -27 -18 -20
Other Income / (Expense), net
0.04 -0.07 0.06 -0.55 -0.23 -0.49 -4.34 0.67 -0.16 2.27 4.76
Income Tax Expense
6.36 4.74 17 4.56 -2.94 -3.41 -13 -15 1.09 -3.69 17
Preferred Stock Dividends Declared
- - - - 0.00 0.00 0.19 1.63 1.63 1.63 1.16
Basic Earnings per Share
$1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Weighted Average Basic Shares Outstanding
11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Diluted Earnings per Share
$1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Weighted Average Diluted Shares Outstanding
11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Weighted Average Basic & Diluted Shares Outstanding
11.50M 11.60M 12M 11.80M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M

Quarterly Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 192 - - - 238
Net Income / (Loss) Attributable to Common Shareholders
18 -2.69 -25 -11 15 8.14 26 27 29 25 35
Consolidated Net Income / (Loss)
18 -2.29 -24 -10 16 8.55 27 27 29 25 35
Net Income / (Loss) Continuing Operations
18 -2.29 -24 -10 16 8.55 27 27 29 25 35
Total Pre-Tax Income
25 -2.29 -31 -14 20 11 34 31 40 37 49
Total Operating Income
20 5.17 -21 -4.38 26 14 36 35 39 40 52
Total Gross Profit
88 80 85 361 124 137 134 147 144 266 179
Total Revenue
137 138 148 191 197 211 228 247 237 266 291
Operating Revenue
137 138 148 191 197 211 228 247 237 266 291
Total Cost of Revenue
49 58 63 -170 73 75 93 100 94 0.00 112
Operating Cost of Revenue
49 58 63 - 73 75 93 100 94 - 112
Total Operating Expenses
68 75 106 365 98 123 98 112 105 226 127
Selling, General & Admin Expense
48 53 79 70 77 82 77 83 74 92 95
Research & Development Expense
11 7.30 10 17 11 17 12 12 11 15 13
Depreciation Expense
15 15 16 23 23 23 23 23 21 20 20
Impairment Charge
- - 0.00 - - - 0.77 - - - 0.00
Other Special Charges / (Income)
-5.26 0.36 0.83 -1.89 -12 1.28 -14 -5.64 -0.18 -0.62 -0.54
Total Other Income / (Expense), net
5.02 -7.46 -11 -9.38 -6.21 -3.37 -2.44 -3.29 1.33 -3.36 -3.33
Interest & Investment Income
-4.60 -4.66 -2.33 0.29 -5.48 -5.44 -4.73 -4.41 -3.77 -2.90 -3.06
Other Income / (Expense), net
9.62 -2.80 -1.18 -9.68 -0.72 2.07 2.29 1.12 5.10 -0.47 -0.28
Income Tax Expense
7.13 0.00 -7.33 -3.49 4.31 1.98 7.18 3.99 11 12 14
Preferred Stock Dividends Declared
0.41 0.41 0.41 0.41 0.41 0.41 0.34 - 0.00 0.00 0.00
Basic Earnings per Share
$0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31 $1.09 $1.54
Weighted Average Basic Shares Outstanding
19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M 21.16M 21.21M
Diluted Earnings per Share
$0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28 $1.05 $1.51
Weighted Average Diluted Shares Outstanding
19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M 21.92M 21.68M
Weighted Average Basic & Diluted Shares Outstanding
20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M 22.97M 22.73M

Annual Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-14 -122 3.78 12 19 -54 92 -52 168 -76 141
Net Cash From Operating Activities
17 27 39 67 46 15 3.32 -31 119 64 185
Net Cash From Continuing Operating Activities
17 27 39 67 46 15 3.32 -31 119 64 185
Net Income / (Loss) Continuing Operations
15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Consolidated Net Income / (Loss)
15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Depreciation Expense
6.90 22 28 34 45 45 47 60 60 68 91
Amortization Expense
6.83 7.28 7.67 8.47 7.02 1.88 2.51 3.96 3.92 14 1.36
Non-Cash Adjustments To Reconcile Net Income
7.43 19 12 11 13 26 16 23 21 49 42
Changes in Operating Assets and Liabilities, net
-19 -25 -7.55 -1.79 -25 -35 -20 -70 16 -48 -28
Net Cash From Investing Activities
-33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Net Cash From Continuing Investing Activities
-33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Purchase of Property, Plant & Equipment
-2.18 -4.57 -10 -5.74 -6.64 -6.14 -2.56 -8.88 -8.87 -16 -14
Acquisitions
-31 -144 -98 -22 -21 -62 -106 -7.61 -9.64 -402 -20
Sale of Property, Plant & Equipment
- - - - 0.00 0.00 2.65 0.75 0.00 14 0.00
Net Cash From Financing Activities
1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Net Cash From Continuing Financing Activities
1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Repayment of Debt
0.00 -0.29 -2.74 -31 -121 -16 75 -3.00 -3.00 -313 -10
Repurchase of Common Equity
0.00 -2.50 - - -1.03 -1.52 -0.89 -1.96 -4.99 -11 -12
Payment of Dividends
- - - - 0.00 0.00 -0.19 -1.63 -1.63 -1.63 -1.16
Issuance of Debt
0.00 0.00 75 0.00 118 15 24 0.00 0.00 641 0.00
Issuance of Common Equity
- - - - 0.00 0.00 70 0.00 81 0.00 0.00
Other Financing Activities, net
1.07 2.07 0.09 2.69 5.74 0.62 2.07 1.46 -3.50 -50 14
Effect of Exchange Rate Changes
- - - - - - - 0.00 0.00 -0.47 -0.23
Cash Interest Paid
4.15 4.08 3.76 6.29 6.09 6.93 9.71 21 31 24 27
Cash Income Taxes Paid
13 9.54 18 6.40 10 4.98 10 0.29 1.23 19 18

Quarterly Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
7.48 12 -95 -0.12 4.94 68 45 23 26 49 61
Net Cash From Operating Activities
18 17 12 16 35 76 44 30 58 57 84
Net Cash From Continuing Operating Activities
18 17 12 16 35 76 44 30 58 57 84
Net Income / (Loss) Continuing Operations
18 -2.29 -24 -10 16 8.55 27 27 29 25 35
Consolidated Net Income / (Loss)
18 -2.29 -24 -10 16 8.55 27 27 29 25 35
Depreciation Expense
15 15 16 23 23 23 23 23 21 20 20
Amortization Expense
0.10 0.10 3.35 11 0.32 0.34 0.34 0.35 0.36 0.36 0.36
Non-Cash Adjustments To Reconcile Net Income
-21 14 17 28 5.27 31 -1.01 10 -6.48 14 28
Changes in Operating Assets and Liabilities, net
6.24 -9.22 0.08 -35 -9.17 13 -4.52 -30 14 -2.47 0.25
Net Cash From Investing Activities
8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11 -3.05 -14
Net Cash From Continuing Investing Activities
8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11 -3.05 -14
Purchase of Property, Plant & Equipment
-4.58 -4.45 -4.81 -2.39 -2.47 -4.01 -6.10 -1.24 -6.07 -3.05 -14
Net Cash From Financing Activities
-20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22 -4.65 -9.83
Net Cash From Continuing Financing Activities
-20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22 -4.65 -9.83
Repayment of Debt
-0.75 -0.75 -308 -4.01 -2.03 -2.03 -2.03 -4.06 -4.06 -4.06 -4.06
Repurchase of Common Equity
-8.66 -1.30 -0.68 -0.32 -10 -0.55 -1.04 -0.61 -20 -0.81 -7.91
Other Financing Activities, net
-9.91 1.01 -41 -0.18 2.53 1.24 9.76 0.04 2.20 0.23 2.15
Effect of Exchange Rate Changes
0.00 - - -0.40 -0.30 0.84 0.58 -1.35 0.16 0.07 0.09
Cash Interest Paid
7.95 8.21 3.08 5.15 8.90 4.97 8.46 4.61 7.82 4.42 7.60
Cash Income Taxes Paid
0.85 16 0.01 1.85 0.29 16 0.14 1.06 -6.07 19 11

Annual Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
285 323 412 431 457 461 772 760 904 1,284 1,440
Total Current Assets
193 103 132 153 188 170 322 344 520 528 753
Cash & Equivalents
155 27 31 43 62 7.86 100 48 221 145 286
Restricted Cash
- - - - - - 0.00 5.01 0.00 0.03 0.04
Short-Term Investments
- - - - - - - - 0.00 6.31 9.13
Accounts Receivable
22 46 59 65 72 96 129 165 162 222 281
Inventories, net
13 26 38 41 48 61 82 105 111 137 143
Prepaid Expenses
1.45 3.56 2.78 4.52 5.07 5.86 11 12 17 19 34
Plant, Property, & Equipment, net
7.13 11 20 38 41 41 53 43 45 57 62
Total Noncurrent Assets
86 209 260 240 229 250 397 373 340 699 625
Goodwill
1.84 1.84 1.84 3.58 3.58 3.58 28 28 28 60 62
Intangible Assets
66 176 230 202 180 189 294 252 209 542 480
Noncurrent Deferred & Refundable Income Taxes
17 26 23 28 38 52 68 81 91 85 69
Other Noncurrent Operating Assets
- 0.00 0.83 1.47 1.22 0.80 2.21 11 12 12 14
Total Liabilities & Shareholders' Equity
285 323 412 431 457 461 772 760 904 1,284 1,440
Total Liabilities
125 153 237 233 244 265 413 422 447 856 900
Total Current Liabilities
12 32 39 166 62 79 88 99 145 194 278
Short-Term Debt
- 0.00 3.35 3.26 9.94 13 0.85 0.85 13 9.20 17
Accounts Payable
2.07 3.39 3.63 8.88 15 11 23 29 37 46 63
Accrued Expenses
5.85 19 22 19 16 17 19 26 34 55 109
Current Deferred & Payable Income Tax Liabilities
0.00 2.40 0.00 5.02 0.00 3.91 - 0.00 8.16 7.52 2.24
Current Employee Benefit Liabilities
1.19 1.63 2.31 3.52 3.74 6.23 8.52 10 24 38 38
Other Current Liabilities
2.65 5.76 8.27 125 17 27 36 33 30 39 50
Total Noncurrent Liabilities
113 121 198 68 182 187 325 322 301 661 622
Long-Term Debt
113 121 198 67 176 172 287 286 285 615 600
Other Noncurrent Operating Liabilities
0.00 0.63 0.00 0.50 6.51 14 39 36 17 47 22
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
160 170 175 197 213 196 334 314 433 404 541
Total Preferred & Common Equity
160 170 175 197 213 196 334 314 433 404 541
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
160 170 175 197 213 196 334 314 433 404 541
Common Stock
164 173 179 187 201 214 388 404 514 520 596
Retained Earnings
-4.35 -2.92 -4.01 11 18 -4.97 -48 -97 -80 -100 -23
Treasury Stock
- 0.00 -0.26 -0.66 -0.72 -2.25 -3.14 -5.09 -10 -21 -33
Accumulated Other Comprehensive Income / (Loss)
- - 0.00 -0.38 -4.87 -11 -3.06 12 8.86 5.34 1.03
Other Equity Adjustments
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
859 890 915 921 1,287 1,292 1,343 1,408 1,422 1,494 1,568
Total Current Assets
459 497 541 555 521 536 603 698 747 825 903
Cash & Equivalents
162 193 229 240 145 150 218 263 311 360 421
Restricted Cash
0.00 0.00 - - 0.04 0.03 0.04 0.04 0.04 0.04 0.04
Short-Term Investments
- - 9.66 6.94 8.30 5.39 5.72 8.86 15 16 16
Accounts Receivable
173 179 172 166 196 220 226 253 255 274 304
Inventories, net
104 107 114 125 148 137 138 146 143 143 136
Prepaid Expenses
12 11 16 17 24 23 15 28 22 32 26
Plant, Property, & Equipment, net
44 44 49 52 57 58 59 64 67 73 82
Total Noncurrent Assets
356 349 325 314 709 698 681 646 608 595 583
Goodwill
28 28 28 28 60 61 61 62 62 62 62
Intangible Assets
230 220 196 183 570 538 520 500 467 450 433
Noncurrent Deferred & Refundable Income Taxes
82 84 88 90 68 88 92 71 67 71 75
Other Noncurrent Operating Assets
16 16 14 13 11 10 8.25 12 12 12 13
Total Liabilities & Shareholders' Equity
859 890 915 921 1,287 1,292 1,343 1,408 1,422 1,494 1,568
Total Liabilities
425 435 438 440 857 849 881 902 860 897 931
Total Current Liabilities
123 134 137 140 190 202 237 271 240 284 329
Short-Term Debt
26 25 1.26 1.69 8.44 11 14 15 19 21 23
Accounts Payable
29 34 49 49 61 53 55 70 70 74 74
Accrued Expenses
27 28 32 40 54 58 84 102 86 114 141
Current Deferred & Payable Income Tax Liabilities
- 0.59 11 0.00 0.00 14 3.29 0.00 5.30 3.53 8.98
Current Employee Benefit Liabilities
11 15 9.53 16 30 22 33 33 16 27 35
Other Current Liabilities
30 31 33 34 37 42 49 50 43 44 46
Total Noncurrent Liabilities
302 301 301 300 667 647 645 632 620 613 602
Long-Term Debt
285 285 285 284 618 612 608 605 594 589 584
Other Noncurrent Operating Liabilities
17 16 16 16 48 36 36 27 26 24 18
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
410 430 452 456 406 419 437 506 562 597 637
Total Preferred & Common Equity
410 430 452 456 406 419 437 506 562 597 637
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
410 430 452 456 406 419 437 506 562 597 637
Common Stock
495 507 524 532 511 531 542 586 608 620 634
Retained Earnings
-90 -81 -62 -65 -90 -85 -77 -51 6.39 31 66
Treasury Stock
-9.18 -9.85 -19 -20 -21 -31 -32 -33 -53 -54 -62
Accumulated Other Comprehensive Income / (Loss)
14 14 9.41 8.33 5.37 3.61 3.31 2.81 0.48 -0.33 -1.17
Other Equity Adjustments
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
36.36% 68.53% 37.49% 13.99% 2.47% 0.93% 3.67% 46.38% 53.87% 26.20% 43.78%
EBITDA Growth
88.89% 6.79% 28.91% 20.38% -12.02% -55.72% -81.24% 415.30% 281.11% -28.95% 145.93%
EBIT Growth
62.36% -38.90% 41.88% 22.64% -53.68% -202.40% -167.33% 21.58% 235.24% -107.37% 3,953.57%
NOPAT Growth
-22.05% -60.65% -120.48% 1,565.46% 15.52% -135.52% -148.46% 11.33% 279.72% -99.08% 22,123.79%
Net Income Growth
-46.52% -74.41% -127.35% 1,539.96% -60.67% -470.00% -88.94% -12.42% 139.21% -198.63% 522.94%
EPS Growth
-49.03% -74.24% -126.47% 1,544.44% -61.54% -476.00% -80.85% 10.29% 127.87% -222.35% 419.23%
Operating Cash Flow Growth
-21.64% 59.13% 43.49% 70.16% -31.97% -66.54% -78.24% -1,039.28% 481.24% -46.19% 189.34%
Free Cash Flow Firm Growth
-3.66% -606.37% 35.34% 275.66% -154.07% 39.18% -312.24% 72.16% 246.82% -548.20% 135.22%
Invested Capital Growth
53.74% 117.06% 31.87% -35.38% 50.68% 11.27% 46.75% 5.74% -6.54% 68.68% -4.25%
Revenue Q/Q Growth
-3.78% 18.60% 5.41% 5.13% -4.24% 4.66% 1.73% 11.76% 8.33% 10.61% 6.83%
EBITDA Q/Q Growth
-5.35% -2.26% 13.11% 7.52% -18.71% 22.61% -80.74% 2,362.17% 4.24% -4.38% 23.44%
EBIT Q/Q Growth
-12.30% -20.04% 27.49% 11.50% -49.41% 23.08% -151.47% 44.89% 11.73% -119.94% 75.78%
NOPAT Q/Q Growth
-47.49% -36.52% -111.66% 3,324.49% 7.85% 23.80% -152.83% 41.99% 4.07% -95.00% 57.33%
Net Income Q/Q Growth
-54.11% -50.14% -114.40% 3,461.84% -62.75% 5.05% -92.76% 29.35% 40.34% -161.20% 93.09%
EPS Q/Q Growth
-55.10% -50.00% -114.29% 6,400.00% -62.96% 4.57% -85.79% 34.13% 66.67% -92.59% 91.91%
Operating Cash Flow Q/Q Growth
-25.92% 36.73% 10.43% 20.53% -32.95% -40.78% -66.10% 19.97% 70.38% -31.09% 8.50%
Free Cash Flow Firm Q/Q Growth
-57.65% 1.50% -194.16% 496.53% -149.62% 69.15% -733.51% 75.94% 145.49% -12.98% 20.47%
Invested Capital Q/Q Growth
-1.12% -3.21% 9.34% -37.04% 52.29% 2.33% 44.94% 1.73% -6.48% -0.30% 0.99%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
83.37% 62.07% 55.31% 63.77% 69.42% 58.19% 53.45% 56.13% 62.71% 100.00% 61.36%
EBITDA Margin
60.89% 38.59% 36.18% 38.21% 32.81% 14.39% 2.60% 9.17% 22.70% 12.78% 23.62%
Operating Margin
42.84% 15.61% 16.02% 17.54% 7.92% -7.68% -18.41% -11.15% 9.65% 0.10% 12.58%
EBIT Margin
42.90% 15.55% 16.05% 17.27% 7.81% -7.92% -20.42% -10.94% 9.62% -0.56% 13.11%
Profit (Net Income) Margin
20.14% 3.06% -0.61% 7.69% 2.95% -10.82% -19.71% -15.14% 3.86% -3.01% 8.87%
Tax Burden Percent
70.75% 45.33% -6.58% 77.27% 193.03% 86.85% 76.00% 76.43% 94.50% 83.39% 81.78%
Interest Burden Percent
66.38% 43.38% 57.60% 57.60% 19.58% 157.25% 127.01% 181.04% 42.45% 644.01% 82.68%
Effective Tax Rate
29.26% 54.67% 106.58% 22.73% -93.03% 0.00% 0.00% 0.00% 5.50% 0.00% 18.22%
Return on Invested Capital (ROIC)
23.59% 4.83% -0.62% 9.76% 11.46% -3.20% -6.13% -4.44% 8.02% 0.06% 10.30%
ROIC Less NNEP Spread (ROIC-NNEP)
38.55% -17.15% 0.00% -2.83% -24.69% -10.99% -14.44% -15.61% -8.49% -6.83% 7.15%
Return on Net Nonoperating Assets (RNNOA)
-13.34% -2.45% 0.00% -1.43% -8.48% -7.84% -9.24% -9.30% -3.31% -4.24% 5.87%
Return on Equity (ROE)
10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -15.37% -13.74% 4.72% -4.18% 16.16%
Cash Return on Invested Capital (CROIC)
-18.77% -69.01% -28.11% 52.74% -28.98% -13.88% -44.02% -10.01% 14.79% -51.07% 14.64%
Operating Return on Assets (OROA)
12.02% 6.58% 7.72% 8.26% 3.63% -3.60% -7.16% -4.52% 5.62% -0.32% 8.50%
Return on Assets (ROA)
5.64% 1.29% -0.29% 3.68% 1.37% -4.91% -6.91% -6.25% 2.26% -1.69% 5.75%
Return on Common Equity (ROCE)
10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -14.68% -12.76% 4.42% -3.95% 15.75%
Return on Equity Simple (ROE_SIMPLE)
9.60% 2.32% -0.62% 7.85% 2.86% -11.52% -12.76% -15.27% 4.34% -4.59% 0.00%
Net Operating Profit after Tax (NOPAT)
23 9.10 -1.86 27 32 -11 -28 -25 44 0.41 91
NOPAT Margin
30.31% 7.08% -1.05% 13.55% 15.28% -5.38% -12.89% -7.81% 9.12% 0.07% 10.28%
Net Nonoperating Expense Percent (NNEP)
-14.96% 21.98% -0.62% 12.59% 36.15% 7.79% 8.31% 11.17% 16.52% 6.89% 3.15%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -4.11% 6.07% 0.04% 7.85%
Cost of Revenue to Revenue
16.63% 37.93% 44.69% 36.23% 30.58% 41.81% 46.55% 43.87% 37.29% 0.00% 38.64%
SG&A Expenses to Revenue
27.72% 21.64% 17.86% 21.86% 27.04% 31.17% 39.00% 39.21% 33.22% 40.63% 35.97%
R&D to Revenue
3.77% 2.26% 5.13% 7.63% 9.59% 7.68% 5.26% 7.05% 7.04% 7.26% 5.85%
Operating Expenses to Revenue
40.53% 46.46% 39.29% 46.23% 61.51% 65.88% 71.86% 67.25% 53.07% 99.90% 48.79%
Earnings before Interest and Taxes (EBIT)
33 20 28 35 16 -17 -44 -35 47 -3.45 116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
46 50 64 77 68 30 5.63 29 111 79 209
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.24 4.14 4.30 2.71 3.50 1.83 1.76 2.24 2.60 2.88 3.28
Price to Tangible Book Value (P/TBV)
5.65 0.00 0.00 0.00 25.87 99.44 49.46 20.77 5.76 0.00 0.00
Price to Revenue (P/Rev)
6.80 5.46 4.25 2.65 3.61 1.72 2.72 2.22 2.31 1.89 2.01
Price to Earnings (P/E)
33.75 178.61 0.00 34.45 122.36 0.00 0.00 0.00 65.69 0.00 22.98
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.96% 0.56% 0.00% 2.90% 0.82% 0.00% 0.00% 0.00% 1.52% 0.00% 4.35%
Enterprise Value to Invested Capital (EV/IC)
4.02 3.09 2.71 2.55 2.62 1.46 1.48 1.68 2.30 1.84 2.43
Enterprise Value to Revenue (EV/Rev)
6.26 6.19 5.21 2.78 4.21 2.57 3.70 3.04 2.52 2.70 2.37
Enterprise Value to EBITDA (EV/EBITDA)
10.28 16.04 14.40 7.29 12.83 17.89 142.06 33.13 11.12 21.14 10.05
Enterprise Value to EBIT (EV/EBIT)
14.59 39.79 32.46 16.13 53.90 0.00 0.00 0.00 26.25 0.00 18.09
Enterprise Value to NOPAT (EV/NOPAT)
20.65 87.44 0.00 20.55 27.53 0.00 0.00 0.00 27.68 4,061.24 23.07
Enterprise Value to Operating Cash Flow (EV/OCF)
27.67 28.97 23.38 8.37 19.05 35.15 240.67 0.00 10.33 25.93 11.32
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 3.80 0.00 0.00 0.00 0.00 15.02 0.00 16.23
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.71 0.71 1.15 0.36 0.87 0.95 0.80 0.85 0.65 1.46 1.14
Long-Term Debt to Equity
0.71 0.71 1.13 0.34 0.83 0.88 0.80 0.84 0.62 1.44 1.11
Financial Leverage
-0.35 0.14 0.74 0.51 0.34 0.71 0.64 0.60 0.39 0.62 0.82
Leverage Ratio
1.82 1.84 2.13 2.27 2.16 2.25 2.22 2.20 2.09 2.47 2.81
Compound Leverage Factor
1.21 0.80 1.23 1.30 0.42 3.53 2.82 3.98 0.89 15.90 2.32
Debt to Total Capital
41.47% 41.56% 53.55% 26.34% 46.61% 48.69% 44.48% 45.84% 39.43% 59.29% 53.30%
Short-Term Debt to Total Capital
0.00% 0.00% 0.89% 1.22% 2.49% 3.47% 0.13% 0.14% 1.74% 0.87% 1.51%
Long-Term Debt to Total Capital
41.47% 41.56% 52.66% 25.13% 44.11% 45.21% 44.35% 45.70% 37.70% 58.42% 51.80%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.85% 3.98% 3.29% 2.36% 0.00%
Common Equity to Total Capital
58.53% 58.44% 46.45% 73.66% 53.39% 51.31% 51.68% 50.19% 57.28% 38.35% 46.70%
Debt to EBITDA
2.44 2.43 3.15 0.92 2.74 6.19 51.06 9.88 2.70 7.95 2.96
Net Debt to EBITDA
-0.89 1.88 2.66 0.36 1.82 5.93 33.24 8.04 0.70 6.02 1.55
Long-Term Debt to EBITDA
2.44 2.43 3.10 0.87 2.59 5.75 50.91 9.85 2.58 7.83 2.87
Debt to NOPAT
4.90 13.25 -108.08 2.58 5.89 -16.56 -10.32 -11.60 6.71 1,526.71 6.79
Net Debt to NOPAT
-1.78 10.25 -91.37 1.01 3.91 -15.86 -6.72 -9.45 1.73 1,156.85 3.55
Long-Term Debt to NOPAT
4.90 13.25 -106.28 2.46 5.57 -15.38 -10.29 -11.57 6.42 1,504.21 6.60
Altman Z-Score
3.87 3.61 2.81 2.11 2.79 1.37 1.22 1.47 2.60 1.49 2.43
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.48% 7.13% 6.24% 5.61% 2.56%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
16.38 3.22 3.35 0.92 3.04 2.17 3.68 3.46 3.57 2.72 2.71
Quick Ratio
15.02 2.29 2.29 0.65 2.18 1.32 2.61 2.15 2.63 1.93 2.07
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-18 -130 -84 148 -80 -49 -200 -56 82 -367 129
Operating Cash Flow to CapEx
790.84% 601.66% 380.16% 1,167.93% 687.73% 248.85% 0.00% -383.99% 1,341.44% 2,351.84% 1,338.81%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -49.09 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.57 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.21 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.28 0.42 0.48 0.48 0.47 0.45 0.35 0.41 0.58 0.56 0.65
Accounts Receivable Turnover
3.89 3.79 3.38 3.26 3.02 2.48 1.93 2.15 2.97 3.20 3.51
Inventory Turnover
1.21 2.47 2.47 1.87 1.42 1.60 1.41 1.48 1.68 0.00 2.44
Fixed Asset Turnover
12.36 14.19 11.26 6.89 5.25 5.10 4.60 6.60 11.08 12.11 14.80
Accounts Payable Turnover
5.38 17.88 22.52 11.67 5.38 6.74 5.88 5.31 5.50 0.00 6.31
Days Sales Outstanding (DSO)
93.80 96.24 108.03 111.93 121.02 147.00 189.41 169.57 122.78 114.01 103.88
Days Inventory Outstanding (DIO)
300.60 148.04 147.58 195.51 256.22 228.17 258.48 245.97 217.73 0.00 149.64
Days Payable Outstanding (DPO)
67.87 20.41 16.21 31.27 67.88 54.16 62.09 68.74 66.35 0.00 57.88
Cash Conversion Cycle (CCC)
326.53 223.87 239.40 276.17 309.37 321.00 385.80 346.80 274.16 114.01 195.64
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
119 258 340 220 331 369 541 572 534 901 863
Invested Capital Turnover
0.78 0.68 0.59 0.72 0.75 0.60 0.48 0.57 0.88 0.86 1.00
Increase / (Decrease) in Invested Capital
42 139 82 -120 111 37 172 31 -37 367 -38
Enterprise Value (EV)
478 796 921 561 869 537 800 961 1,229 1,660 2,096
Market Capitalization
519 703 751 534 746 359 588 703 1,127 1,162 1,774
Book Value per Share
$13.92 $14.64 $15.00 $16.64 $17.60 $15.84 $26.18 $17.96 $21.17 $19.20 $24.07
Tangible Book Value per Share
$7.99 ($0.69) ($4.88) ($0.67) $2.38 $0.29 $0.93 $1.94 $9.57 ($9.42) ($0.06)
Total Capital
274 290 376 268 399 381 646 625 756 1,053 1,158
Total Debt
113 121 202 71 186 186 287 287 298 624 617
Total Long-Term Debt
113 121 198 67 176 172 287 286 285 615 600
Net Debt
-41 93 170 28 123 178 187 233 77 473 322
Capital Expenditures (CapEx)
2.18 4.57 10 5.74 6.64 6.14 -0.09 8.13 8.87 2.72 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)
26 44 65 -52 74 97 135 192 166 192 198
Debt-free Net Working Capital (DFNWC)
181 71 96 -9.42 136 105 235 246 387 343 492
Net Working Capital (NWC)
181 71 92 -13 126 92 234 245 374 334 475
Net Nonoperating Expense (NNE)
7.76 5.17 -0.79 12 25 11 15 23 26 19 13
Net Nonoperating Obligations (NNO)
-41 88 165 23 118 173 182 233 77 473 322
Total Depreciation and Amortization (D&A)
14 30 36 42 52 47 50 64 64 82 93
Debt-free, Cash-free Net Working Capital to Revenue
34.25% 33.97% 36.52% -26.01% 35.65% 46.59% 62.36% 60.82% 34.17% 31.25% 22.38%
Debt-free Net Working Capital to Revenue
236.93% 55.25% 54.13% -4.67% 65.83% 50.37% 108.77% 77.65% 79.59% 55.86% 55.75%
Net Working Capital to Revenue
236.93% 55.25% 52.24% -6.29% 61.01% 44.01% 108.38% 77.38% 76.90% 54.36% 53.77%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Adjusted Weighted Average Basic Shares Outstanding
11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Adjusted Diluted Earnings per Share
$1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Adjusted Weighted Average Diluted Shares Outstanding
11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Adjusted Basic & Diluted Earnings per Share
$1.34 $0.00 $0.00 $0.00 $0.51 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
11.46M 11.60M 11.66M 11.86M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M
Normalized Net Operating Profit after Tax (NOPAT)
23 19 20 27 11 -11 -20 -18 47 1.55 66
Normalized NOPAT Margin
30.31% 14.57% 11.57% 13.55% 5.57% -5.23% -9.12% -5.72% 9.61% 0.25% 7.52%
Pre Tax Income Margin
28.48% 6.75% 9.25% 9.95% 1.53% -12.45% -25.94% -19.81% 4.08% -3.62% 10.84%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.83 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.45% -3.39% 8.65% -8.77% 1.48%
Augmented Payout Ratio
0.00% 63.55% 0.00% 0.00% 16.92% -6.75% -2.54% -7.48% 35.21% -67.94% 17.06%

Quarterly Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 22,424,968.00 22,745,482.00 22,970,352.00
DEI Adjusted Shares Outstanding
- - - - - - - - 22,424,968.00 22,745,482.00 22,970,352.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 1.32 1.09 1.53
Growth Metrics
- - - - - - - - - - -
Revenue Growth
28.70% 18.44% 12.52% 44.75% 43.43% 53.12% 53.58% 29.64% 20.46% 25.87% 27.64%
EBITDA Growth
75.05% -38.76% -107.64% -15.74% 8.86% 130.65% 2,459.90% 130.34% 34.06% 51.54% 17.09%
EBIT Growth
203.57% -80.82% -221.16% -309.98% -14.91% 573.83% 277.55% 563.28% 72.71% 150.53% 35.22%
NOPAT Growth
121.95% -75.48% -192.68% -137.36% 40.79% 211.86% 298.69% 1,090.71% 38.75% 138.85% 31.53%
Net Income Growth
1,165.25% -136.62% -343.12% -989.70% -13.87% 473.81% 210.14% 367.52% 88.07% 189.05% 32.05%
EPS Growth
1,266.67% -148.28% -382.22% -1,000.00% -15.85% 357.14% 188.98% 353.33% 85.51% 191.67% 33.63%
Operating Cash Flow Growth
-14.73% -15.57% -61.22% -64.55% 91.53% 335.35% 253.17% 91.47% 66.83% -25.25% 90.19%
Free Cash Flow Firm Growth
410.18% 598.54% -5,726.90% -911.35% -616.24% -585.08% 122.47% 118.55% 124.53% 116.78% 8.05%
Invested Capital Growth
-9.70% -11.00% 58.22% 68.68% 73.77% 65.52% -5.47% -4.25% -6.73% -3.29% -5.47%
Revenue Q/Q Growth
4.39% 0.44% 7.46% 28.48% 3.44% 7.23% 7.78% 8.45% -3.88% 12.04% 9.30%
EBITDA Q/Q Growth
95.82% -61.63% -115.18% 838.45% 152.99% -18.69% 55.36% -4.30% 10.90% -8.09% 20.04%
EBIT Q/Q Growth
347.26% -92.09% -1,015.96% 35.23% 281.24% -37.33% 141.35% -6.84% 22.57% -9.09% 30.27%
NOPAT Q/Q Growth
77.94% -75.21% -496.96% 78.66% 770.59% -45.09% 152.91% 6.39% -6.08% -5.48% 39.28%
Net Income Q/Q Growth
1,476.36% -112.56% -956.67% 57.48% 252.60% -45.48% 211.35% 3.28% 7.28% -16.21% 42.24%
EPS Q/Q Growth
1,540.00% -117.07% -807.14% 64.57% 253.33% -47.83% 213.89% 0.89% 12.28% -17.97% 43.81%
Operating Cash Flow Q/Q Growth
-59.17% -4.68% -28.37% 27.14% 120.62% 116.66% -41.89% -31.07% 92.23% -2.92% 47.85%
Free Cash Flow Firm Q/Q Growth
55.56% -4.37% -611.40% -6.65% 1.02% 10.14% 123.69% -11.98% 30.91% -38.54% 52.59%
Invested Capital Q/Q Growth
-1.87% -0.91% 73.99% -0.30% 1.09% -5.62% -0.63% 0.99% -1.53% -2.13% -2.87%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
64.23% 58.20% 57.48% 189.17% 62.95% 64.70% 59.01% 59.42% 60.59% 100.00% 61.64%
EBITDA Margin
32.54% 12.43% -1.76% 10.10% 24.70% 18.73% 27.00% 23.82% 27.49% 22.55% 24.77%
Operating Margin
14.78% 3.74% -13.83% -2.30% 13.29% 6.57% 15.91% 14.07% 16.38% 15.21% 18.01%
EBIT Margin
21.78% 1.72% -14.63% -7.37% 12.92% 7.55% 16.91% 14.53% 18.53% 15.03% 17.92%
Profit (Net Income) Margin
13.25% -1.66% -16.29% -5.39% 7.96% 4.04% 11.68% 11.13% 12.42% 9.29% 12.09%
Tax Burden Percent
71.87% 100.00% 76.72% 74.67% 78.46% 81.23% 78.75% 87.33% 73.32% 66.61% 71.67%
Interest Burden Percent
84.63% -96.54% 145.16% 97.92% 78.47% 65.93% 87.73% 87.71% 91.43% 92.76% 94.13%
Effective Tax Rate
28.14% 0.00% 0.00% 0.00% 21.54% 18.77% 21.25% 12.67% 26.68% 33.39% 28.33%
Return on Invested Capital (ROIC)
9.95% 2.56% -7.29% -1.38% 9.79% 5.78% 11.78% 12.30% 12.60% 11.72% 16.17%
ROIC Less NNEP Spread (ROIC-NNEP)
12.44% -3.71% -10.61% -4.00% 7.90% 4.53% 11.31% 11.58% 12.85% 11.01% 15.25%
Return on Net Nonoperating Assets (RNNOA)
4.40% -0.76% -7.07% -2.48% 4.42% 2.11% 9.93% 9.50% 9.66% 6.58% 6.94%
Return on Equity (ROE)
14.35% 1.80% -14.36% -3.86% 14.21% 7.89% 21.71% 21.81% 22.25% 18.30% 23.11%
Cash Return on Invested Capital (CROIC)
18.78% 18.56% -43.98% -51.07% -53.26% -47.81% 12.19% 14.64% 18.13% 16.84% 20.45%
Operating Return on Assets (OROA)
13.42% 1.04% -7.46% -4.14% 7.89% 4.99% 10.38% 9.42% 12.61% 10.37% 12.54%
Return on Assets (ROA)
8.16% -1.00% -8.31% -3.03% 4.86% 2.67% 7.17% 7.21% 8.45% 6.41% 8.46%
Return on Common Equity (ROCE)
13.48% 1.70% -13.56% -3.64% 13.45% 7.47% 21.13% 21.25% 21.70% 17.87% 23.11%
Return on Equity Simple (ROE_SIMPLE)
7.87% 5.93% -1.75% 0.00% -5.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
15 3.62 -14 -3.06 21 11 29 30 29 27 38
NOPAT Margin
10.62% 2.62% -9.68% -1.61% 10.43% 5.34% 12.53% 12.29% 12.01% 10.13% 12.91%
Net Nonoperating Expense Percent (NNEP)
-2.50% 6.27% 3.32% 2.62% 1.89% 1.25% 0.47% 0.72% -0.26% 0.71% 0.92%
Return On Investment Capital (ROIC_SIMPLE)
- - - -0.30% 1.97% 1.07% 2.53% 2.62% 2.42% 2.23% 3.02%
Cost of Revenue to Revenue
35.77% 41.80% 42.52% -89.17% 37.05% 35.30% 40.99% 40.58% 39.41% 0.00% 38.36%
SG&A Expenses to Revenue
34.94% 38.27% 53.31% 36.58% 38.82% 38.69% 33.65% 33.51% 31.02% 34.45% 32.62%
R&D to Revenue
7.65% 5.29% 6.83% 8.73% 5.36% 7.82% 5.40% 4.96% 4.46% 5.54% 4.47%
Operating Expenses to Revenue
49.45% 54.46% 71.31% 191.46% 49.66% 58.13% 43.10% 45.34% 44.21% 84.79% 43.63%
Earnings before Interest and Taxes (EBIT)
30 2.37 -22 -14 25 16 39 36 44 40 52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
45 17 -2.61 19 49 40 61 59 65 60 72
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.22 2.93 3.09 2.88 3.48 3.24 3.93 3.28 3.07 3.15 2.62
Price to Tangible Book Value (P/TBV)
6.40 5.46 0.00 0.00 0.00 0.00 0.00 0.00 52.80 22.18 11.79
Price to Revenue (P/Rev)
2.82 2.48 2.26 1.89 2.16 1.89 2.40 2.01 1.87 1.92 1.60
Price to Earnings (P/E)
42.96 52.60 0.00 0.00 0.00 0.00 50.96 22.98 18.87 17.44 14.28
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.33% 1.90% 0.00% 0.00% 0.00% 0.00% 1.96% 4.35% 5.30% 5.73% 7.00%
Enterprise Value to Invested Capital (EV/IC)
2.92 2.69 1.94 1.84 2.14 2.14 2.73 2.43 2.37 2.55 2.28
Enterprise Value to Revenue (EV/Rev)
2.96 2.60 3.16 2.70 2.89 2.46 2.83 2.37 2.18 2.16 1.77
Enterprise Value to EBITDA (EV/EBITDA)
11.79 11.78 21.35 21.14 23.65 17.51 13.82 10.05 8.93 8.62 7.18
Enterprise Value to EBIT (EV/EBIT)
22.87 24.59 101.37 0.00 0.00 323.32 35.45 18.09 14.97 13.37 10.70
Enterprise Value to NOPAT (EV/NOPAT)
32.27 36.67 214.32 4,061.24 430.92 172.76 40.46 23.07 20.47 18.54 14.93
Enterprise Value to Operating Cash Flow (EV/OCF)
13.21 12.43 18.88 25.93 24.16 13.20 13.69 11.32 9.65 11.18 8.03
Enterprise Value to Free Cash Flow (EV/FCFF)
14.74 13.67 0.00 0.00 0.00 0.00 21.80 16.23 12.60 14.86 10.82
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.60 0.60 1.45 1.46 1.40 1.35 1.23 1.14 1.09 1.02 0.95
Long-Term Debt to Equity
0.60 0.59 1.44 1.44 1.38 1.32 1.20 1.11 1.06 0.99 0.92
Financial Leverage
0.35 0.21 0.67 0.62 0.56 0.46 0.88 0.82 0.75 0.60 0.45
Leverage Ratio
2.06 1.95 2.46 2.47 2.40 2.40 2.88 2.81 2.70 2.68 2.60
Compound Leverage Factor
1.74 -1.88 3.57 2.42 1.88 1.58 2.52 2.47 2.47 2.49 2.45
Debt to Total Capital
37.48% 37.31% 59.26% 59.29% 58.42% 57.40% 55.09% 53.30% 52.19% 50.55% 48.80%
Short-Term Debt to Total Capital
0.17% 0.22% 0.80% 0.87% 1.07% 1.26% 1.36% 1.51% 1.64% 1.77% 1.88%
Long-Term Debt to Total Capital
37.32% 37.09% 58.46% 58.42% 57.35% 56.14% 53.73% 51.80% 50.55% 48.78% 46.92%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
3.26% 3.24% 2.35% 2.36% 2.33% 2.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
59.26% 59.44% 38.39% 38.35% 39.25% 40.30% 44.91% 46.70% 47.81% 49.45% 51.20%
Debt to EBITDA
2.20 2.41 7.63 7.95 7.55 5.93 3.67 2.96 2.73 2.49 2.37
Net Debt to EBITDA
0.37 0.33 5.76 6.02 5.67 3.80 2.06 1.55 1.28 0.96 0.67
Long-Term Debt to EBITDA
2.19 2.39 7.53 7.83 7.41 5.80 3.58 2.87 2.64 2.40 2.28
Debt to NOPAT
6.03 7.50 76.59 1,526.71 137.65 58.51 10.74 6.79 6.24 5.35 4.93
Net Debt to NOPAT
1.00 1.02 57.85 1,156.85 103.36 37.48 6.04 3.55 2.93 2.05 1.39
Long-Term Debt to NOPAT
6.01 7.45 75.56 1,504.21 135.13 57.22 10.48 6.60 6.05 5.16 4.74
Altman Z-Score
3.11 2.86 1.47 1.46 1.84 1.80 2.31 2.25 2.39 2.47 2.35
Noncontrolling Interest Sharing Ratio
6.09% 5.43% 5.61% 5.61% 5.40% 5.27% 2.65% 2.56% 2.47% 2.35% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.95 3.97 2.74 2.72 2.66 2.54 2.58 2.71 3.12 2.91 2.75
Quick Ratio
3.00 2.95 1.84 1.93 1.86 1.90 1.94 2.07 2.43 2.29 2.25
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
71 68 -347 -370 -366 -329 78 69 90 55 84
Operating Cash Flow to CapEx
0.00% 391.41% 259.23% 662.49% 1,414.35% 1,888.69% 721.86% 2,441.08% 961.06% 1,855.57% 620.55%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -46.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 1.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.62 0.61 0.51 0.56 0.61 0.66 0.61 0.65 0.68 0.69 0.70
Accounts Receivable Turnover
2.98 3.18 2.96 3.20 3.43 3.82 3.68 3.51 3.88 3.91 3.74
Inventory Turnover
1.77 1.81 1.75 0.00 0.19 0.31 0.48 2.44 2.58 2.04 2.16
Fixed Asset Turnover
11.27 11.23 11.01 12.11 12.63 13.48 13.75 14.80 14.74 14.77 14.35
Accounts Payable Turnover
4.70 5.40 4.70 0.00 0.47 0.79 1.09 6.31 5.90 4.47 4.24
Days Sales Outstanding (DSO)
122.43 114.80 123.28 114.01 106.34 95.66 99.09 103.88 94.00 93.29 97.63
Days Inventory Outstanding (DIO)
205.70 201.24 208.06 0.00 1,920.11 1,179.91 755.85 149.64 141.66 178.83 169.06
Days Payable Outstanding (DPO)
77.66 67.60 77.60 0.00 783.25 461.88 335.39 57.88 61.91 81.58 86.18
Cash Conversion Cycle (CCC)
250.46 248.43 253.74 114.01 1,243.19 813.69 519.55 195.64 173.75 190.54 180.50
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
524 520 904 901 911 860 855 863 850 832 808
Invested Capital Turnover
0.94 0.98 0.75 0.86 0.94 1.08 0.94 1.00 1.05 1.16 1.25
Increase / (Decrease) in Invested Capital
-56 -64 333 367 387 340 -49 -38 -61 -28 -47
Enterprise Value (EV)
1,530 1,399 1,753 1,660 1,950 1,837 2,337 2,096 2,012 2,117 1,840
Market Capitalization
1,457 1,336 1,255 1,162 1,458 1,413 1,988 1,774 1,724 1,883 1,669
Book Value per Share
$21.44 $21.73 $19.29 $19.20 $19.23 $20.16 $23.31 $24.07 $25.07 $26.26 $27.74
Tangible Book Value per Share
$10.80 $11.66 ($10.66) ($9.42) ($8.29) ($6.65) ($2.60) ($0.06) $1.46 $3.73 $6.16
Total Capital
763 767 1,057 1,053 1,067 1,084 1,126 1,158 1,176 1,208 1,244
Total Debt
286 286 627 624 623 622 620 617 614 610 607
Total Long-Term Debt
285 284 618 615 612 608 605 600 594 589 584
Net Debt
48 39 473 473 468 398 349 322 288 235 171
Capital Expenditures (CapEx)
-8.93 4.45 4.81 2.39 2.47 4.01 6.10 1.24 6.07 3.05 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)
167 170 186 192 191 156 172 198 201 187 161
Debt-free Net Working Capital (DFNWC)
405 417 340 343 346 379 443 492 527 563 597
Net Working Capital (NWC)
404 415 331 334 334 366 428 475 508 542 574
Net Nonoperating Expense (NNE)
-3.61 5.91 9.80 7.21 4.87 2.73 1.92 2.87 -0.98 2.24 2.39
Net Nonoperating Obligations (NNO)
48 39 473 473 468 398 349 322 288 235 171
Total Depreciation and Amortization (D&A)
15 15 19 33 23 24 23 23 21 20 20
Debt-free, Cash-free Net Working Capital to Revenue
32.21% 31.56% 33.57% 31.25% 28.29% 20.86% 20.76% 22.38% 21.74% 19.14% 15.47%
Debt-free Net Working Capital to Revenue
78.25% 77.40% 61.17% 55.86% 51.31% 50.78% 53.59% 55.75% 57.04% 57.56% 57.37%
Net Working Capital to Revenue
78.01% 77.09% 59.66% 54.36% 49.62% 48.94% 51.74% 53.77% 54.95% 55.38% 55.13%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31 $1.09 $1.54
Adjusted Weighted Average Basic Shares Outstanding
19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M 21.16M 21.21M
Adjusted Diluted Earnings per Share
$0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28 $1.05 $1.51
Adjusted Weighted Average Diluted Shares Outstanding
19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M 21.92M 21.68M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M 22.97M 22.73M
Normalized Net Operating Profit after Tax (NOPAT)
11 3.87 -14 -4.39 11 12 18 25 28 27 37
Normalized NOPAT Margin
7.87% 2.80% -9.29% -2.30% 5.61% 5.83% 7.89% 10.30% 11.95% 9.97% 12.78%
Pre Tax Income Margin
18.43% -1.66% -21.23% -7.22% 10.14% 4.98% 14.84% 12.74% 16.94% 13.94% 16.87%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -2.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 -1.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -3.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -2.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
4.57% 6.02% -22.92% -8.77% -7.72% -15.91% 3.85% 1.48% 0.82% 0.32% 0.00%
Augmented Payout Ratio
32.98% 46.22% -176.24% -67.94% -66.16% -129.03% 33.22% 17.06% 24.65% 20.84% 24.90%

Financials Breakdown Chart

Key Financial Trends

ANI Pharmaceuticals’ financial statements show a business that has expanded significantly since 2022. Revenue increased from $83.8 million in Q3 2022 to $266.0 million in Q2 2026, although the latest quarter included a notable sequential rebound from $237.5 million in Q1 2026. The company has also remained profitable in each of the reported quarters since Q1 2025, following losses in Q3 and Q4 2024.

  • Strong revenue growth: Revenue rose approximately 26% year over year in Q2 2026 and more than tripled compared with Q3 2022. This indicates meaningful expansion in ANI’s commercial business and product portfolio.
  • Improved earnings: Q2 2026 net income increased to $24.7 million from $8.5 million in the restated Q2 2025 period. Diluted EPS rose to $1.05 from $0.36, providing a substantial improvement for shareholders.
  • Operating profitability has strengthened: Operating income was $40.5 million in Q2 2026, compared with $13.9 million in Q2 2025 and operating losses in Q3 and Q4 2024. This suggests that higher revenue is translating into improved operating leverage.
  • Cash generation remains solid: ANI generated $56.7 million in operating cash flow in Q2 2026 and $115.0 million during the first half of 2026. Operating cash flow has generally remained positive throughout the provided period, even during quarters with reported net losses.
  • Liquidity has improved materially: Cash and equivalents reached $360.2 million at June 30, 2026, up from $217.8 million at June 30, 2025 and $56.3 million at September 30, 2022. Including short-term investments, the company held roughly $376.5 million in readily available funds.
  • Balance-sheet equity has expanded: Total common equity increased to $597.2 million in Q2 2026 from $436.8 million a year earlier. Total assets also reached approximately $1.49 billion, reflecting the company’s larger operating scale.
  • Debt has begun to decline: Total debt was approximately $610.5 million at the end of Q2 2026, down from roughly $622.0 million in Q2 2025. With cash and short-term investments increasing, estimated net debt improved to approximately $234 million.
  • Acquisitions and capital investment continue: ANI spent $5.3 million on acquisitions and $3.1 million on property and equipment in Q1 and Q2 2026 combined. These investments could support future growth, but they also require the company to generate sufficient returns from acquired products and facilities.
  • Working capital was a modest cash drag in Q2: Changes in operating assets and liabilities reduced operating cash flow by $2.5 million in Q2 2026, compared with a $13.1 million benefit in Q2 2025. Investors should monitor receivables and inventory as the company grows.
  • Leverage remains meaningful: Long-term debt stood at $589.2 million and total liabilities were $896.9 million in Q2 2026. Although liquidity has improved, interest costs remain significant, with $4.4 million of cash interest paid in the latest quarter.
  • Share count has increased recently: Basic weighted-average shares rose to 21.2 million in Q2 2026 from 19.8 million in Q2 2025. Recent share repurchases may offset some dilution, but the higher share count can limit per-share earnings growth if it persists.
  • Asset concentration creates impairment risk: Intangible assets totaled $449.9 million, representing roughly 30% of total assets, while goodwill added another $62.5 million. These balances can be vulnerable to impairment charges if acquired products underperform or expected cash flows decline.
  • Q2 2026 gross-profit data should be treated cautiously: The supplied statement reports zero cost of revenue and gross profit equal to revenue, implying a 100% gross margin. This is inconsistent with prior quarters, which reported gross margins between roughly 60% and 65%, and may reflect a classification or data-standardization issue rather than a sustainable margin improvement.

Overall, ANI Pharmaceuticals’ trend is favorable: revenue, profitability, cash, and equity have all improved substantially from the 2022–2024 period. The primary risks are the company’s still-elevated debt burden, reliance on intangible assets and acquisitions, recent share-count growth, and uncertainty surrounding the reported Q2 2026 cost-of-revenue figure. Investors should focus on whether future quarters confirm the latest earnings improvement and the company’s ability to convert that growth into consistent free cash flow.

11/17/26 05:41 PM ETAI Generated. May Contain Errors.

ANI Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ANI Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ANI Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $78.34 million in 2025, rising from $15.38 million in 2015. The previous period was -$18.52 million in 2024. View ANI Pharmaceuticals' forecast to see where analysts expect ANI Pharmaceuticals to go next.

ANI Pharmaceuticals' total operating income in 2025 was $111.09 million, based on the following breakdown:
  • Total Gross Profit: $542.06 million
  • Total Operating Expenses: $430.96 million

Over the last 10 years, ANI Pharmaceuticals' total revenue changed from $76.32 million in 2015 to $883.37 million in 2025, a change of 1,057.4%.

In the past 13 quarters, ANI Pharmaceuticals' cash and equivalents has ranged from $144.98 million in Q3 2024 to $420.76 million in Q3 2026, and is currently $420.76 million as of their latest financial filing in Q3 2026.

ANI Pharmaceuticals had total debt of $617.20 million at the end of 2025, a 1.1% decrease from 2024, and a 444.1% increase since 2015.

Over the last 10 years, ANI Pharmaceuticals' book value per share changed from 13.92 in 2015 to 24.07 in 2025, a change of 72.9%.



Financial statements for NASDAQ:ANIP last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners